Title |
A Chlamydomonas-Derived Human Papillomavirus 16 E7 Vaccine Induces Specific Tumor Protection
|
---|---|
Published in |
PLOS ONE, April 2013
|
DOI | 10.1371/journal.pone.0061473 |
Pubmed ID | |
Authors |
Olivia C. Demurtas, Silvia Massa, Paola Ferrante, Aldo Venuti, Rosella Franconi, Giovanni Giuliano |
Abstract |
The E7 protein of the Human Papillomavirus (HPV) type 16, being involved in malignant cellular transformation, represents a key antigen for developing therapeutic vaccines against HPV-related lesions and cancers. Recombinant production of this vaccine antigen in an active form and in compliance with good manufacturing practices (GMP) plays a crucial role for developing effective vaccines. E7-based therapeutic vaccines produced in plants have been shown to be active in tumor regression and protection in pre-clinical models. However, some drawbacks of in whole-plant vaccine production encouraged us to explore the production of the E7-based therapeutic vaccine in Chlamydomonas reinhardtii, an organism easy to grow and transform and fully amenable to GMP guidelines. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | <1% |
Denmark | 1 | <1% |
Italy | 1 | <1% |
South Africa | 1 | <1% |
Unknown | 145 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 26 | 17% |
Student > Master | 26 | 17% |
Student > Bachelor | 25 | 17% |
Student > Ph. D. Student | 24 | 16% |
Student > Doctoral Student | 8 | 5% |
Other | 18 | 12% |
Unknown | 22 | 15% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 51 | 34% |
Biochemistry, Genetics and Molecular Biology | 47 | 32% |
Immunology and Microbiology | 6 | 4% |
Medicine and Dentistry | 6 | 4% |
Engineering | 5 | 3% |
Other | 8 | 5% |
Unknown | 26 | 17% |